The stock of Synairgen plc (LON:SNG) is a huge mover today! The stock decreased 5.56% or GBX 1 on November 9, hitting GBX 17. About 17,500 shares traded hands. Synairgen plc (LON:SNG) has declined 33.33% since April 8, 2016 and is downtrending. It has underperformed by 38.12% the S&P500.
The move comes after 7 months positive chart setup for the GBX 15.53 million company. It was reported on Nov, 9 by Barchart.com. We have GBX 29.92 PT which if reached, will make LON:SNG worth GBX 11.80M more.
Synairgen plc (LON:SNG) Ratings Coverage
Out of 2 analysts covering Synairgen PLC (LON:SNG), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Synairgen PLC has been the topic of 12 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock of Synairgen plc (LON:SNG) has “Buy” rating given on Thursday, September 22 by N+1 Singer. FinnCap maintained the shares of SNG in a report on Thursday, September 22 with “Corporate” rating. The firm earned “Corporate” rating on Tuesday, August 30 by FinnCap. The company was maintained on Tuesday, March 22 by FinnCap. The firm earned “Buy” rating on Wednesday, September 16 by N+1 Singer. The company was maintained on Tuesday, November 17 by FinnCap. On Wednesday, September 16 the stock rating was maintained by FinnCap with “Corporate”. FinnCap maintained Synairgen plc (LON:SNG) on Wednesday, October 12 with “Corporate” rating. N+1 Singer maintained Synairgen plc (LON:SNG) on Wednesday, July 22 with “Buy” rating. The firm has “Buy” rating given on Thursday, January 28 by N+1 Singer.
More recent Synairgen plc (LON:SNG) news were published by: Reuters.com which released: “Synairgen slumps by a third as AstraZeneca ditches asthma drug study” on October 12, 2016. Also Marketwatch.com published the news titled: “Synairgen PLC” on June 10, 2011. Fool.Co.Uk‘s news article titled: “Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?” with publication date: June 07, 2016 was also an interesting one.
Synairgen plc is a holding company. The Firm is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). The company has a market cap of 15.53 million GBP. The Firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. It currently has negative earnings. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.